14alpha, 17alpha-ethano-16alpha-hydroxy-estratrienes

14alpha, 17alpha-ethano-16alpha-hydroxy-estratrienes

New 14alpha, 17alpha-bridged oestratrienes of formula (I) are claimed. When OR3 is in the alpha-configuration: R1, R2, R3 = H, -CO-R4 or -(CH2)n-CO2H, where n = 1-4. R1 may also be benzyl, 1-8C alkyl or 3-5C cycloalkyl; R4 = an organic gp. with up to 11C atoms. When OR3 is in the beta-configuration:...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: LAURENT HENRY DR, BULL JAMES R DR, KIRSCH GERALD DR, BEIER SYBILLE DR, WIECHERT RUDOLF PROF DR, ELGER WALTER DR, NEEF GUNTER DR, ESPERLING PETER
Format: Patent
Sprache:eng
Schlagworte:
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
STEROIDS
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator LAURENT HENRY DR
BULL JAMES R DR
KIRSCH GERALD DR
BEIER SYBILLE DR
WIECHERT RUDOLF PROF DR
ELGER WALTER DR
NEEF GUNTER DR
ESPERLING PETER
description New 14alpha, 17alpha-bridged oestratrienes of formula (I) are claimed. When OR3 is in the alpha-configuration: R1, R2, R3 = H, -CO-R4 or -(CH2)n-CO2H, where n = 1-4. R1 may also be benzyl, 1-8C alkyl or 3-5C cycloalkyl; R4 = an organic gp. with up to 11C atoms. When OR3 is in the beta-configuration: R1, R2, R3 = H or 1-12C acyl; R1 may also be 1-8C alkyl. In both cases, A-B is an etheno or etheno bridging bond. 18 cpds. are specifically claimed, including 3-benzyloxy-14alpha, 17alpha-ethano- 1, 3, 5(10)oestratriene-16alpha, 17beta-diol and 14alpha, 17alpha-ethano -1, 3, 5(10) oestratriene-3, 16alpha, 17beta-triol. Also claimed is a method of preparing (I), e.g. from 3, 16beta, 17beta-triacetoxy-14alpha, 17alpha-ethano-1, 3, 5 (10)-oestratriene-16alpha-carbonitrile. For treating disorders involving oestrogen deficiency, unit oral dose is 0.001-0.05 mg. Solns. for intramuscular injection contain 0.01-1 mg (I) per ml, and vaginal salves contain 0.1-10 mg (I) per 100 ml. For contraception, tablets contain 0.003-0.05 mg (I) and 0.05-0.5 mg of a gestagen.
format Patent
fullrecord <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_IE67321B1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>IE67321B1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_IE67321B13</originalsourceid><addsrcrecordid>eNrjZDAxNEnMKchI1FEwNAczdFNLMhLz8nUNzSDcjMqUovyKSt3U4pKixJKizNS81GIeBta0xJziVF4ozc0g5-Ya4uyhm1qQH59aXJCYDFRVEu_pamZubGToZGhMUAEAw0kqzg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>14alpha, 17alpha-ethano-16alpha-hydroxy-estratrienes</title><source>esp@cenet</source><creator>LAURENT HENRY DR ; BULL JAMES R DR ; KIRSCH GERALD DR ; BEIER SYBILLE DR ; WIECHERT RUDOLF PROF DR ; ELGER WALTER DR ; NEEF GUNTER DR ; ESPERLING PETER</creator><creatorcontrib>LAURENT HENRY DR ; BULL JAMES R DR ; KIRSCH GERALD DR ; BEIER SYBILLE DR ; WIECHERT RUDOLF PROF DR ; ELGER WALTER DR ; NEEF GUNTER DR ; ESPERLING PETER</creatorcontrib><description>New 14alpha, 17alpha-bridged oestratrienes of formula (I) are claimed. When OR3 is in the alpha-configuration: R1, R2, R3 = H, -CO-R4 or -(CH2)n-CO2H, where n = 1-4. R1 may also be benzyl, 1-8C alkyl or 3-5C cycloalkyl; R4 = an organic gp. with up to 11C atoms. When OR3 is in the beta-configuration: R1, R2, R3 = H or 1-12C acyl; R1 may also be 1-8C alkyl. In both cases, A-B is an etheno or etheno bridging bond. 18 cpds. are specifically claimed, including 3-benzyloxy-14alpha, 17alpha-ethano- 1, 3, 5(10)oestratriene-16alpha, 17beta-diol and 14alpha, 17alpha-ethano -1, 3, 5(10) oestratriene-3, 16alpha, 17beta-triol. Also claimed is a method of preparing (I), e.g. from 3, 16beta, 17beta-triacetoxy-14alpha, 17alpha-ethano-1, 3, 5 (10)-oestratriene-16alpha-carbonitrile. For treating disorders involving oestrogen deficiency, unit oral dose is 0.001-0.05 mg. Solns. for intramuscular injection contain 0.01-1 mg (I) per ml, and vaginal salves contain 0.1-10 mg (I) per 100 ml. For contraception, tablets contain 0.003-0.05 mg (I) and 0.05-0.5 mg of a gestagen.</description><edition>5</edition><language>eng</language><subject>CHEMISTRY ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS ; STEROIDS</subject><creationdate>1996</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=19960320&amp;DB=EPODOC&amp;CC=IE&amp;NR=67321B1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25542,76290</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=19960320&amp;DB=EPODOC&amp;CC=IE&amp;NR=67321B1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>LAURENT HENRY DR</creatorcontrib><creatorcontrib>BULL JAMES R DR</creatorcontrib><creatorcontrib>KIRSCH GERALD DR</creatorcontrib><creatorcontrib>BEIER SYBILLE DR</creatorcontrib><creatorcontrib>WIECHERT RUDOLF PROF DR</creatorcontrib><creatorcontrib>ELGER WALTER DR</creatorcontrib><creatorcontrib>NEEF GUNTER DR</creatorcontrib><creatorcontrib>ESPERLING PETER</creatorcontrib><title>14alpha, 17alpha-ethano-16alpha-hydroxy-estratrienes</title><description>New 14alpha, 17alpha-bridged oestratrienes of formula (I) are claimed. When OR3 is in the alpha-configuration: R1, R2, R3 = H, -CO-R4 or -(CH2)n-CO2H, where n = 1-4. R1 may also be benzyl, 1-8C alkyl or 3-5C cycloalkyl; R4 = an organic gp. with up to 11C atoms. When OR3 is in the beta-configuration: R1, R2, R3 = H or 1-12C acyl; R1 may also be 1-8C alkyl. In both cases, A-B is an etheno or etheno bridging bond. 18 cpds. are specifically claimed, including 3-benzyloxy-14alpha, 17alpha-ethano- 1, 3, 5(10)oestratriene-16alpha, 17beta-diol and 14alpha, 17alpha-ethano -1, 3, 5(10) oestratriene-3, 16alpha, 17beta-triol. Also claimed is a method of preparing (I), e.g. from 3, 16beta, 17beta-triacetoxy-14alpha, 17alpha-ethano-1, 3, 5 (10)-oestratriene-16alpha-carbonitrile. For treating disorders involving oestrogen deficiency, unit oral dose is 0.001-0.05 mg. Solns. for intramuscular injection contain 0.01-1 mg (I) per ml, and vaginal salves contain 0.1-10 mg (I) per 100 ml. For contraception, tablets contain 0.003-0.05 mg (I) and 0.05-0.5 mg of a gestagen.</description><subject>CHEMISTRY</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><subject>STEROIDS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>1996</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZDAxNEnMKchI1FEwNAczdFNLMhLz8nUNzSDcjMqUovyKSt3U4pKixJKizNS81GIeBta0xJziVF4ozc0g5-Ya4uyhm1qQH59aXJCYDFRVEu_pamZubGToZGhMUAEAw0kqzg</recordid><startdate>19960320</startdate><enddate>19960320</enddate><creator>LAURENT HENRY DR</creator><creator>BULL JAMES R DR</creator><creator>KIRSCH GERALD DR</creator><creator>BEIER SYBILLE DR</creator><creator>WIECHERT RUDOLF PROF DR</creator><creator>ELGER WALTER DR</creator><creator>NEEF GUNTER DR</creator><creator>ESPERLING PETER</creator><scope>EVB</scope></search><sort><creationdate>19960320</creationdate><title>14alpha, 17alpha-ethano-16alpha-hydroxy-estratrienes</title><author>LAURENT HENRY DR ; BULL JAMES R DR ; KIRSCH GERALD DR ; BEIER SYBILLE DR ; WIECHERT RUDOLF PROF DR ; ELGER WALTER DR ; NEEF GUNTER DR ; ESPERLING PETER</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_IE67321B13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>1996</creationdate><topic>CHEMISTRY</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><topic>STEROIDS</topic><toplevel>online_resources</toplevel><creatorcontrib>LAURENT HENRY DR</creatorcontrib><creatorcontrib>BULL JAMES R DR</creatorcontrib><creatorcontrib>KIRSCH GERALD DR</creatorcontrib><creatorcontrib>BEIER SYBILLE DR</creatorcontrib><creatorcontrib>WIECHERT RUDOLF PROF DR</creatorcontrib><creatorcontrib>ELGER WALTER DR</creatorcontrib><creatorcontrib>NEEF GUNTER DR</creatorcontrib><creatorcontrib>ESPERLING PETER</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>LAURENT HENRY DR</au><au>BULL JAMES R DR</au><au>KIRSCH GERALD DR</au><au>BEIER SYBILLE DR</au><au>WIECHERT RUDOLF PROF DR</au><au>ELGER WALTER DR</au><au>NEEF GUNTER DR</au><au>ESPERLING PETER</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>14alpha, 17alpha-ethano-16alpha-hydroxy-estratrienes</title><date>1996-03-20</date><risdate>1996</risdate><abstract>New 14alpha, 17alpha-bridged oestratrienes of formula (I) are claimed. When OR3 is in the alpha-configuration: R1, R2, R3 = H, -CO-R4 or -(CH2)n-CO2H, where n = 1-4. R1 may also be benzyl, 1-8C alkyl or 3-5C cycloalkyl; R4 = an organic gp. with up to 11C atoms. When OR3 is in the beta-configuration: R1, R2, R3 = H or 1-12C acyl; R1 may also be 1-8C alkyl. In both cases, A-B is an etheno or etheno bridging bond. 18 cpds. are specifically claimed, including 3-benzyloxy-14alpha, 17alpha-ethano- 1, 3, 5(10)oestratriene-16alpha, 17beta-diol and 14alpha, 17alpha-ethano -1, 3, 5(10) oestratriene-3, 16alpha, 17beta-triol. Also claimed is a method of preparing (I), e.g. from 3, 16beta, 17beta-triacetoxy-14alpha, 17alpha-ethano-1, 3, 5 (10)-oestratriene-16alpha-carbonitrile. For treating disorders involving oestrogen deficiency, unit oral dose is 0.001-0.05 mg. Solns. for intramuscular injection contain 0.01-1 mg (I) per ml, and vaginal salves contain 0.1-10 mg (I) per 100 ml. For contraception, tablets contain 0.003-0.05 mg (I) and 0.05-0.5 mg of a gestagen.</abstract><edition>5</edition><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language eng
recordid cdi_epo_espacenet_IE67321B1
source esp@cenet
subjects CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
STEROIDS
title 14alpha, 17alpha-ethano-16alpha-hydroxy-estratrienes
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T08%3A58%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=LAURENT%20HENRY%20DR&rft.date=1996-03-20&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EIE67321B1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true